» Articles » PMID: 17555582

Practical Methods for Incorporating Summary Time-to-event Data into Meta-analysis

Overview
Journal Trials
Publisher Biomed Central
Date 2007 Jun 9
PMID 17555582
Citations 2957
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In systematic reviews and meta-analyses, time-to-event outcomes are most appropriately analysed using hazard ratios (HRs). In the absence of individual patient data (IPD), methods are available to obtain HRs and/or associated statistics by carefully manipulating published or other summary data. Awareness and adoption of these methods is somewhat limited, perhaps because they are published in the statistical literature using statistical notation.

Methods: This paper aims to 'translate' the methods for estimating a HR and associated statistics from published time-to-event-analyses into less statistical and more practical guidance and provide a corresponding, easy-to-use calculations spreadsheet, to facilitate the computational aspects.

Results: A wider audience should be able to understand published time-to-event data in individual trial reports and use it more appropriately in meta-analysis. When faced with particular circumstances, readers can refer to the relevant sections of the paper. The spreadsheet can be used to assist them in carrying out the calculations.

Conclusion: The methods cannot circumvent the potential biases associated with relying on published data for systematic reviews and meta-analysis. However, this practical guide should improve the quality of the analysis and subsequent interpretation of systematic reviews and meta-analyses that include time-to-event outcomes.

Citing Articles

Prognostic value of circular RNAs expression and their correlation with clinicopathological features in acute myeloid leukemia: a systematic review and meta-analysis.

Mirazimi Y, Aghayan A, Atashi A, Mohammadi D, Rafiee M Ann Hematol. 2025; .

PMID: 40087154 DOI: 10.1007/s00277-025-06300-6.


Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis.

Souto Filho J, Cantadori L, Crusoe E, Hungria V, Maiolino A Blood Cancer J. 2025; 15(1):37.

PMID: 40082415 PMC: 11906644. DOI: 10.1038/s41408-025-01253-5.


The Prognostic Role of miR-375 in Head and Neck Squamous Cell Carcinoma: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.

Dioguardi M, Musella G, Bizzoca M, Sovereto D, Guerra C, Laterza P Int J Mol Sci. 2025; 26(5).

PMID: 40076805 PMC: 11900050. DOI: 10.3390/ijms26052183.


Osteopontin as a prognostic biomarker in head and neck cancer- a systematic review and meta-analysis.

Piyarathne N, Hettiarachchi K, Yuwanati M, Sivaramakrishnan G, Ramanathan A, Jayasinghe R Evid Based Dent. 2025; .

PMID: 40074805 DOI: 10.1038/s41432-025-01133-8.


Characterization of alternative sPD-1 isoforms reveals that ECD sPD-1 signature predicts an efficient antitumor response.

Hou P, Hu L, Zhang J, Zhou X, Xiao Y, Li L Commun Biol. 2025; 8(1):406.

PMID: 40069413 PMC: 11897324. DOI: 10.1038/s42003-025-07800-x.


References
1.
DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

2.
Yusuf S, Peto R, Lewis J, Collins R, Sleight P . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985; 27(5):335-71. DOI: 10.1016/s0033-0620(85)80003-7. View

3.
Dickersin K, Min Y, Meinert C . Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA. 1992; 267(3):374-8. View

4.
Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G . Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst. 1989; 81(19):1464-71. DOI: 10.1093/jnci/81.19.1464. View

5.
Dickersin K . The existence of publication bias and risk factors for its occurrence. JAMA. 1990; 263(10):1385-9. View